References
- Russek HI, Zohman BL, Dorset VJ. Effects of tobacco and whiskey on the cardiovascular system. J Am Med Assoc. 1955;157(7):563–568.
- Clarke CN, Clarke NE, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci [Internet]. 1956;232(6):654–666. Available from: http://www.ncbi.nlm.nih.gov/pubmed/13372537
- Kitchell JR, Meltzer LE, Seven MJ. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis [Internet]. 1961;3:338–349. Available from: http://www.ncbi.nlm.nih.gov/pubmed/13756462
- Kitchell JR, Palmon F, Aytan N, et al. The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiol [Internet]. 1963;11:501–506. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14033183
- Lewin MR. Chelation therapy for cardiovascular disease. Review and commentary. Tex Heart Inst J [Internet]. 1997;24(2):81–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9205980
- Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc. 1990;82(3):173–177.
- Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996;10(3):78–86.
- Lamar CP. Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology. 1964;15:379–395.
- American College for Advancement in Medicine. Our approach [Internet]. [cited 2016 Mar 2]. Available from http://www.acam.org/?page=Approach
- International College of Integrative Medicine. Who Are We? [Internet]. [cited 2016 Mar 2]. Available from http://www.icimed.com/who_are_we.php
- Rozema T. The protocol for the safe and effective administration of edta and other chelating agents for vascular disease, degenerative disease, and metal toxicity. J Adv Med. 1997;10(1):5–100.
- U.S. Food and Drug Administration. Drugs [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; [updated 2013 Aug 23]. [cited 2016 Jan 4]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113738.htm
- Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J. 2000;140(1):4–5.
- Guldager B, Jelnes R, Jørgensen SJ, et al. EDTA treatment of intermittent claudication–a double-blind, placebo-controlled study. J Intern Med [Internet]. 1992;231(3): 261–267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1556523
- van Rij AM, Solomon C, Packer SG, et al. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation [Internet]. 1994;90(3):1194–1199. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8087928
- Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA [Internet]. 2002;287(4):481–486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11798370
- Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev [Internet]. 2002;(4):CD002785. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12519577
- Clarke TC, Black LI, Stussman BJ, et al. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015;79:1–16.
- EDTA Chelation Therapy For Coronary Artery Disease. National Center for Complementary and Alternative Medicine and the National Heart, Lung, and Blood Institute. RFA: RFA-AT-01-004. 2001. [cited 2016 Jan 4]. Available form http://grants.nih.gov/grants/guide/rfa-files/rfa-at-01-004.html
- Nasim NT. The black swan. 2nd ed. New York: Random House; 2010.
- Nash RA. Metals in medicine. Altern Ther Health Med [Internet]. 2005;11(4):18–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16053118
- Waters RS, Bryden NA, Patterson KY, et al. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res [Internet]. 2001;83(3):207–221. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11794513
- Agency for Toxic Substances & Disease Registry. The priority list of hazardous substances that will be the subject of toxicological profiles. Atlanta (GA): Division of Toxicology and Human Health Sciences; 2014.
- Solenkova NV, Newman JD, Berger JS, et al. Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure. Am Heart J [Internet]. 2014;168(6):812–822. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25458643
- Agarwal S, Zaman T, Tuzcu EM, et al. Heavy metals and cardiovascular disease: results from the national health and nutrition examination survey (NHANES) 1999-2006. Angiology. 2011;62(5):422–429.
- Arenas I, Navas-Acien A, Lamas G. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients receiving edetate disodium-based infusion. J Am Coll Cardiol [Internet]. 2016;67(13):2125. Available from: http://linkinghub.elsevier.com/retrieve/pii/S073510971632126X
- Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda) [Internet]. 2013;28(6):391–403. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24186934
- Delile H, Blichert-Toft J, Goiran J-P, et al. Lead in ancient Rome’s city waters. Proc Natl Acad Sci U S A. 2014;111(18):6594–6599.
- National Institutes of Health. Request for information (RFI): the impact of environmental lead exposure on cognition and bone function. Bethesda (MD): Fogarty International Center, National Institute on Aging, Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Institute of Environmental Health Science; 2015.
- Bridbord K, Hanson D. A personal perspective on the initial federal health-based regulation to remove lead from gasoline. Environ Health Perspect. 2009;117(8):1195–1201.
- Annest JL, Pirkle JL, Makuc D, et al. Chronological trend in blood lead levels between 1976 and 1980. N Engl J Med [Internet]. 1983;308(23):1373–1377. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6188954
- Centers for Disease Control and Prevention (CDC). Blood lead levels–United States, 1988-1991. MMWR Morb Mortal Wkly Rep [Internet]. 1994;43(30):545–548. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8035771
- Hanna-Attisha M, LaChance J, Sadler RC, et al. Elevated blood lead levels in children associated with the flint drinking water crisis: a spatial analysis of risk and public health response. Am J Public Health. 2016;106(2):283–290.
- Frank T. Feds promote artificial turf as safe despite health concerns. USA Today. 2015.
- Todd A, Wetmur JG, Moline JM, et al. Unraveling the chronic toxicity of lead: an essential priority for environmental health. Env Heal Perspect. 1996 Mar;104(Suppl 1):141–146.
- U.S. Department of Health and Human Services. Toxicological Profile for Lead. Atlanta (GA): Agency for Toxic Substances and Disease Registry; 2007.
- Hu H, Shih R, Rothenberg S, et al. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect [Internet]. 2007;115(3):455–462. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17431499
- Fiorim J, Ribeiro Júnior RF, Silveira EA, et al. Low-level lead exposure increases systolic arterial pressure and endothelium-derived vasodilator factors in rat aortas. PLoS One. 2011;6(2):e17117.
- Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med [Internet]. 1995;18(2):321–336. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7744317
- Sanders T, Liu Y, Buchner V, et al. Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health. 2009;24(1):15–45.
- Vaziri ND, Khan M. Interplay of reactive oxygen species and nitric oxide in the pathogenesis of experimental lead-induced hypertension. Clin Exp Pharmacol Physiol [Internet]. 2007;34(9):920–925. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17645641
- Hanna CW, Bloom MS, Robinson WP, et al. DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF. Hum Reprod [Internet]. 2012;27(5): 1401–1410. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22381621
- Muntner P, Menke A, DeSalvo KB, et al. Continued decline in blood lead levels among adults in the United States: the national health and nutrition examination surveys. Arch Intern Med [Internet]. 2005;165(18):2155–2161. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16217007
- Navas-Acien A, Selvin E, Sharrett AR, et al. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation [Internet]. 2004;109(25):3196–3201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15184277
- Weisskopf MG, Jain N, Nie H, et al. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the department of veterans affairs normative aging study. Circulation [Internet]. 2009;120(12): 1056–1064. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19738141
- Tellez-Plaza M, Navas-Acien A, Caldwell KL, et al. Reduction in cadmium exposure in the United States population, 1988-2008: the contribution of declining smoking rates. Environ Health Perspect. 2012;120(2):204–209.
- Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol [Internet]. 2015;12(11):627–642. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26461967
- Baldantoni D, Morra L, Zaccardelli M, et al. Cadmium accumulation in leaves of leafy vegetables. Ecotoxicol Environ Saf. 2016;123:89–94.
- Tellez-Plaza M, Guallar E, Fabsitz RR, et al. Cadmium exposure and incident peripheral arterial disease. Circ Cardiovasc Qual Outcomes [Internet]. 2013;6(6): 626–633. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24255048
- Suwazono Y, Kido T, Nakagawa H, et al. Biological half-life of cadmium in the urine of inhabitants after cessation of cadmium exposure. Biomarkers. 2009;14(2):77–81.
- Järup L, Rogenfelt A, Elinder CG, et al. Biological half-time of cadmium in the blood of workers after cessation of exposure. Scand J Work Environ Health [Internet]. 1983;9(4):327–331. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6635611
- Schwartz GG, Il’yasova D, Ivanova A. Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III. Diabetes Care [Internet]. 2003;26(2):468–470. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12547882
- Tellez-Plaza M, Navas-Acien A, Menke A, et al. Cadmium exposure and all-cause and cardiovascular mortality in the U.S. general population. Environ Health Perspect [Internet]. 2012;120(7):1017–1022. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22472185
- Tellez-Plaza M, Guallar E, Howard BV, et al. Cadmium exposure and incident cardiovascular disease. Epidemiology [Internet]. 2013;24(3): 421–429. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23514838
- Ezzati TM, Massey JT, Waksberg J, et al. Sample design: third national health and nutrition examination survey. Vital Health Stat 2. 1992;2(113):1–35.
- U.S. Department of Health and Human Services. The national health and nutrition examination survey: sample design, 1999–2006. Hyattsville (MD): US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics; 2012. DHHS Publication No. (PHS) 2012-1355.
- Lee ET, Welty TK, Fabsitz R, et al. The strong heart study. a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;132(6):1141–1155.
- Messner B, Knoflach M, Seubert A, et al. Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance. Arterioscler Thromb Vasc Biol [Internet]. 2009;29(9): 1392–1398. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19556524
- Ferramola ML, Pérez Díaz MFF, Honoré SM, et al. Cadmium-induced oxidative stress and histological damage in the myocardium. Effects of a soy-based diet. Toxicol Appl Pharmacol [Internet]. 2012;265(3): 380–389. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22995158
- Bergström G, Fagerberg B, Sallsten G, et al. Is cadmium exposure associated with the burden, vulnerability and rupture of human atherosclerotic plaques? Plos One [Internet]. 2015;10(3):e0121240. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25816093
- Ruiz-Hernandez A, Kuo -C-C, Rentero-Garrido P, et al. Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence. Clin Epigenetics [Internet]. 2015;7(1): 55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25984247
- Martín-Núñez E, Donate-Correa J, Muros-de-Fuentes M, et al. Implications of Klotho in vascular health and disease. World J Cardiol [Internet]. 2014;6(12):1262–1269. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25548616
- Frizzell N, Baynes JW. Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem [Internet]. 2013;5(10):1075–1078. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23795964
- Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA [Internet]. 2013;309(12): 1241–1250. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23532240
- Lamas GA, Goertz C, Boineau R, et al. Design of the trial to assess chelation therapy (TACT). Am Heart J [Internet]. 2012;163(1): 7–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22172430
- Lamas GA, Boineau R, Goertz C, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the trial to assess chelation therapy. Am Heart J [Internet]. 2014;168(1):37–44.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24952858
- American Diabetes Association Diabetes. Fast facts - data and statistics about diabetes [Internet]. Alexandria (VA): American Diabetes Association; 2014. Available from http://professional.diabetes.org/content/fast-facts-data-and-statistics-about-diabetes
- Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the trial to assess chelation therapy (TACT). Circ Cardiovasc Qual Outcomes [Internet]. 2014;7(1): 15–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24254885
- Kaul S. Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: an alternative perspective. Circ Cardiovasc Qual Outcomes. 2014;7(1):5–7.
- Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med. 1999;130(12):1005–1013.
- Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol. 2004;43(11):1929–1939.
- Lamas GA, Boineau R, Goertz C, et al. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med. 2013;159(12):797–805.
- Fihn SD, Blankenship JC, Alexander KP, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749–1767.